Table 3.

Ear assessments and nasopharyngeal carriage at the end of therapy

	Amoxicillin	Placebo
	n = 52	n = 51
Mean duration of therapy (months)	5.7	5.2
Mean age (months) at the end of therapy	11.5	10.2
Number of children (%) with the following worst ear status at the end of therapy
	Amoxicillin	Placebo	Risk Difference
	n = 52	n = 51	[95% CI]
Success (bilateral normal ears at 2 successive monthly visits)	5 (9.6%)	0	+9.6% [1.6, 17.6]
Normal	6 (12%)	0	+12% [3, 20]
OME	28 (54%)	26 (51%)	+3% [-16, 22]
AOM without perforation	12 (23%)	11 (22%)	+1.5% [-15, 18]
AOM with perforation	5 (10%)	11 (22%)	-12% [-26, 2]
Dry perforation	0	1 (2%)	-2% [-6, 2]
CSOM	1 (2%)	2 (4%)	-2% [-9, 5]
Any suppurative OM†	18 (35%)	24 (47%)	-12% [-31, 6]
Any perforation‡	6 (12%)	14 (27%)	-16% [-31, -1]
Any active perforation§	6 (12%)	13 (26%)	-14% [-29, 1]
Bilateral AOM without perforation	4 (8%)	7 (13%)	+5% [-6, 17]
Bilateral any perforation‡	1 (2%)	7 (14%)	-12% [-22, -2]
Number of children (%) with nasopharyngeal carriage of the following OM pathogens¥ at end of therapy
	Amoxicillin	Placebo	Risk Difference
	n = 50	n = 47	[95% CI]
Streptococcus pneumoniae	29 (58%)	33 (70%)	-12% [-31, 7]
non-capsular Haemophilus influenzae	36 (72%)	29 (62%)	+10% [-8, 29]
Moraxella catarrhalis	44 (88%)	43 (91%)	-3% [-16,9]
All Spn, NCHi and M.cat	23 (46%)	21 (45%)	1% [-19, 21]
Penicillin non-susceptible Spn‡	17 (34%)	19 (40%)	-6% [-26, 13]
Penicillin resistant Spn††	1 (2%)	2 (4%)	-2.3% [-9, 5]
NCHi beta-lactamase positive	6 (12%)	1 (2%)	+10% [-0.03, 20]

≸AOM, AOMwiP or CSOM; ‡ AOMwiP, dry perforation or CSOM; §AOMwiP or CSOM; ¥ Spn Streptococcus pneumoniae. NCHi non-capsular Haemophilus influenzae. Mcat Moraxella catarrhalis. ‡Penicillin intermediate or resistant Spn (MIC > = 0.1 μg/ml) ††Penicillin resistant Spn (MIC > 1.0 μg/ml)